Developing a new method for targeted drug delivery using antibody complexes
Evaluation of Non-covalent Antibody Drug Complexes (ADCx) for Targeted Drug Delivery
This study is testing a new way to deliver cancer and autoimmune treatments that could make them safer and more effective by using special antibody-drug combinations to target the right cells, and it aims to help patients get better results without the usual side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11015192 on NIH RePORTER |
What this research studies
This research focuses on creating a novel drug delivery system that utilizes non-covalent antibody-drug complexes (ADCx) to target specific cells more effectively. By binding an anti-drug antibody to a drug outside the body and using a secondary ligand to direct it to the desired cell type, this approach aims to improve the safety and efficacy of treatments, particularly for cancers and autoimmune conditions. The study seeks to eliminate the need for traditional linker payloads, which often lead to adverse effects and treatment failures. Patients may benefit from a more effective and safer treatment option if the ADCx method proves successful.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with cancers or autoimmune conditions that are currently treated with antibody-drug conjugates.
Not a fit: Patients who do not have cancer or autoimmune conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective cancer and autoimmune disease treatments with fewer side effects.
How similar studies have performed: While antibody-drug conjugates have been widely studied, this non-covalent approach is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Bordeau, Brandon — University of Michigan at Ann Arbor
- Study coordinator: Bordeau, Brandon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.